Skip to main content
. 2024 Nov 15;16(11):4392–4401. doi: 10.4251/wjgo.v16.i11.4392

Figure 1.

Figure 1

Selection criteria. uHCC: Unresectable hepatocellular carcinoma; C-TACE-P-L: Conventional transarterial chemoembolization combined with lenvatinib plus programmed cell death 1 inhibitor; D-TACE-P-L: Drug-eluting beads transarterial chemoembolization combined with lenvatinib plus programmed cell death 1 inhibitor; ECOG-PS: Eastern Cooperative Oncology Group Performance Status.